ZELRIBO

Serial Number 98848247
661

Registration Progress

Application Filed
Nov 12, 2024
Under Examination
Approved for Publication
Published for Opposition
Registered

Attorney Assistance

Important Deadline Approaching

Non-Final Action E-Mailed
Due: August 07, 2025 (31 days remaining)

Missing this deadline could result in abandonment or cancellation of your trademark.

Basic Information

Serial Number
98848247
Filing Date
November 12, 2024
Drawing Code
4

Status Summary

Current Status
Active
Status Code
661
Status Date
Jul 3, 2025
Application
Pending
Classes
005

Rights Holder

PRG S&Tech Inc.

03
Address
9F, 252 Geumjeong-ro, Geumjeong-gu
Busan 46274
KR

Ownership History

PRG S&Tech Inc.

Original Applicant
03
Busan KR

Legal Representation

Attorney
Sangwon Kim

USPTO Deadlines

Next Renewal Deadline
31 days remaining
Non-Final Action E-Mailed
Due Date
August 07, 2025
Extension Available
Until November 07, 2025

Application History

9 events
Date Code Type Description
Jul 3, 2025 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 3, 2025 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 3, 2025 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE
May 7, 2025 CNRT R NON-FINAL ACTION WRITTEN
May 7, 2025 GNRT F NON-FINAL ACTION E-MAILED
May 7, 2025 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 15, 2025 DOCK D ASSIGNED TO EXAMINER
Nov 12, 2024 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 12, 2024 NWAP I NEW APPLICATION ENTERED

Detailed Classifications

Class 005
Drug delivery agents in the form of tablets that provide controlled release of the active ingredients for symptom improvement and treatment of Hutchinson-Gilford Progeria Syndrome (HGPS) patients for medical purposes; pharmaceutical products for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS); medicinal preparations for symptom improvement and treatment of Hutchinson-Gilford Progeria Syndrome (HGPS) for human purposes; pharmaceutical products for the treatment of progeria; pharmaceutical preparations for the treatment of disorders of the endocrine system; pharmaceutical preparations acting on the central nervous system for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS)

Classification

International Classes
005